AMMIC: New platform for Catalan companies and organizations accelerates drug R&D for minority diseases
Acceleradora en Malalties Minoritàries de Catalunya (AMMIC) is part of the RIS3CAT community coordinated by Biocat. It is led by IUCT and other members include VHIR, Esteve, Aromics, BCN Peptides, Minoryx, Aniling and Qgenomics
After its first year of work, the AMMIC project has seen its first scientific results, including the launch of a phase II/III study in Adrenoleukodystrophy, the preclinical assessment with animal models of the efficacy of three new candidate molecules to treat Malignant pleural mesothelioma, Pediatric Rhabdomyosarcoma and Myotonic dystrophy type 1.
Follow the new here